These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 9676913)

  • 1. Topical modulation of interleukin-1 activity in corneal neovascularization.
    Dana MR; Zhu SN; Yamada J
    Cornea; 1998 Jul; 17(4):403-9. PubMed ID: 9676913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Local suppression of IL-1 by receptor antagonist in the rat model of corneal alkali injury.
    Yamada J; Dana MR; Sotozono C; Kinoshita S
    Exp Eye Res; 2003 Feb; 76(2):161-7. PubMed ID: 12565803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interleukin-1 receptor antagonist therapy and induction of anterior chamber-associated immune deviation-type tolerance after corneal transplantation.
    Yamada J; Zhu SN; Streilein JW; Dana MR
    Invest Ophthalmol Vis Sci; 2000 Dec; 41(13):4203-8. PubMed ID: 11095616
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of cell adhesion molecules on limbal and neovascular endothelium in corneal inflammatory neovascularization.
    Zhu SN; Dana MR
    Invest Ophthalmol Vis Sci; 1999 Jun; 40(7):1427-34. PubMed ID: 10359324
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Topical interleukin 1 receptor antagonist promotes corneal transplant survival.
    Dana MR; Yamada J; Streilein JW
    Transplantation; 1997 May; 63(10):1501-7. PubMed ID: 9175817
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interleukin 1 receptor antagonist suppresses allosensitization in corneal transplantation.
    Yamada J; Dana MR; Zhu SN; Alard P; Streilein JW
    Arch Ophthalmol; 1998 Oct; 116(10):1351-7. PubMed ID: 9790635
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Topical application of culture supernatant from human amniotic epithelial cells suppresses inflammatory reactions in cornea.
    Kamiya K; Wang M; Uchida S; Amano S; Oshika T; Sakuragawa N; Hori J
    Exp Eye Res; 2005 May; 80(5):671-9. PubMed ID: 15862174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interleukin-1 receptor antagonist suppresses Langerhans cell activity and promotes ocular immune privilege.
    Dana MR; Dai R; Zhu S; Yamada J; Streilein JW
    Invest Ophthalmol Vis Sci; 1998 Jan; 39(1):70-7. PubMed ID: 9430547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced experimental corneal neovascularization along with aberrant angiogenic factor expression in the absence of IL-1 receptor antagonist.
    Lu P; Li L; Liu G; Zhang X; Mukaida N
    Invest Ophthalmol Vis Sci; 2009 Oct; 50(10):4761-8. PubMed ID: 19458323
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monoclonal antibody based enzyme-linked and chemiluminescent assays for the human interleukin-1 receptor antagonist. Application to measure hIL-1ra levels in monocyte cultures and synovial fluids.
    Towbin H; Schmitz A; van Oostrum J; Seitz M; Dewald B; Zingel O; Motz J; Vosbeck K; Rordorf C
    J Immunol Methods; 1994 Mar; 170(1):125-35. PubMed ID: 8157985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The inflammatory milieu associated with conjunctivalized cornea and its alteration with IL-1 RA gene therapy.
    Moore JE; McMullen TC; Campbell IL; Rohan R; Kaji Y; Afshari NA; Usui T; Archer DB; Adamis AP
    Invest Ophthalmol Vis Sci; 2002 Sep; 43(9):2905-15. PubMed ID: 12202509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of topical interleukin-1 vs tumor necrosis factor-alpha blockade with corticosteroid therapy on murine corneal inflammation, neovascularization, and transplant survival (an American Ophthalmological Society thesis).
    Dana R
    Trans Am Ophthalmol Soc; 2007; 105():330-43. PubMed ID: 18427620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Topical administration of the kappa opioid receptor agonist nalfurafine suppresses corneal neovascularization and inflammation.
    Shokirova H; Inomata T; Saitoh T; Zhu J; Fujio K; Okumura Y; Yanagawa A; Fujimoto K; Sung J; Eguchi A; Miura M; Nagino K; Hirosawa K; Kuwahara M; Akasaki Y; Nagase H; Murakami A
    Sci Rep; 2021 Apr; 11(1):8647. PubMed ID: 33883646
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NK1 receptor antagonists as a new treatment for corneal neovascularization.
    Bignami F; Giacomini C; Lorusso A; Aramini A; Rama P; Ferrari G
    Invest Ophthalmol Vis Sci; 2014 Sep; 55(10):6783-94. PubMed ID: 25228541
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interleukin-1 receptor antagonist eye drops promoting high-risk corneal allografts survival in rats.
    Jie Y; Zhang WH; Pan ZQ; Wu YY; Wang Y
    Chin Med J (Engl); 2004 May; 117(5):711-6. PubMed ID: 15161539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of interleukin-1 but not tumor necrosis factor suppresses neovascularization in rat models of corneal angiogenesis and adjuvant arthritis.
    Coxon A; Bolon B; Estrada J; Kaufman S; Scully S; Rattan A; Duryea D; Hu YL; Rex K; Pacheco E; Van G; Zack D; Feige U
    Arthritis Rheum; 2002 Oct; 46(10):2604-12. PubMed ID: 12384918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of the course of brain inflammation on the endogenous IL-1beta/IL-1Ra balance in the model of brain delayed-type hypersensitivity response to bacillus Calmette-Guérin in Lewis rats.
    Palin K; Verrier D; Tridon V; Hurst J; Perry VH; Dantzer R; Lestage J
    J Neuroimmunol; 2004 Apr; 149(1-2):22-30. PubMed ID: 15020061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo mucosal delivery of bioactive human interleukin 1 receptor antagonist produced by Streptococcus gordonii.
    Ricci S; Macchia G; Ruggiero P; Maggi T; Bossù P; Xu L; Medaglini D; Tagliabue A; Hammarström L; Pozzi G; Boraschi D
    BMC Biotechnol; 2003 Sep; 3():15. PubMed ID: 13129437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of topical interleukin-1 receptor antagonist (IL-1ra) on corneal allograft survival in presensitized hosts.
    Dekaris IJ; Yamada JJ; Streilein WJ; Dana RM
    Curr Eye Res; 1999 Nov; 19(5):456-9. PubMed ID: 10520223
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo suppression of early experimental osteoarthritis by interleukin-1 receptor antagonist using gene therapy.
    Pelletier JP; Caron JP; Evans C; Robbins PD; Georgescu HI; Jovanovic D; Fernandes JC; Martel-Pelletier J
    Arthritis Rheum; 1997 Jun; 40(6):1012-9. PubMed ID: 9182910
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.